- Exelixis is eligible to receive a milestone payment of $40 million for the approval of the second-line treatment of HCC
- In May of 2018, the FDA accepted for filiing an sNDA for... read more
uBiome announced on 9/... read more
MicuRx Pharmaceuticals, Inc. announced on 9/21/18 the receipt of the qualified infectious disease product (QIDP) classification and grant of fast track... read more
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,